Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc has shown a promising increase in grant revenue, rising to $4.4 million in 2023, indicating strong support for its Rhenium (186Re) Obisbemeda development from CPRIT. The preliminary results from the clinical trials reveal a favorable progression and survival signal for their lead candidate, suggesting a meaningful therapeutic benefit that could enhance patient outcomes beyond typical expectations. Additionally, the advancement of CNSide’s CSF assay platform positions Plus Therapeutics strategically to optimize clinical decision-making and reinforce its leadership in the development of innovative therapies within CNS oncology.

Bears say

Plus Therapeutics Inc. reported a significant decrease in cash and investments, falling from $8.6 million at the end of 2023 to $4.8 million in the third quarter of 2024, raising concerns about its financial stability and ability to fund ongoing clinical development. The company faces substantial challenges within the central nervous system cancer treatment landscape, where existing therapies struggle with efficacy and tolerability, compounded by the heterogeneity of tumors and their propensity for rapid treatment resistance. Furthermore, the risk factors outlined, including potential failures in clinical trials, regulatory approval, and financial viability due to competition and changing economic conditions, contribute to a negative outlook on the stock.

PSTV has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 6 analysts, PSTV has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.